Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 49, 2019 - Issue 11
228
Views
9
CrossRef citations to date
0
Altmetric
Animal Pharmacokinetics and Metabolism

Pharmacokinetic interaction between shuanghuanglian and azithromycin injection: a nonlinear mixed-effects model analysis in rats

, , &
Pages 1344-1351 | Received 10 Oct 2018, Accepted 16 Nov 2018, Published online: 18 Jan 2019

References

  • Bi J, Li X, Liu J, et al. (2017). Population pharmacokinetics of peginterferon alpha2a in patients with chronic hepatitis B. Sci Rep 7:7893.
  • Chen H, Min J, Li W, et al. (2016). The pharmacokinetics change of cefepime after Shuanghuanglian injection administration in subjects with the renal damage. Drug Chem Toxicol 39:129–36.
  • Filist M, Buś-Kwaśnik K, Ksycińska H, Rudzki PJ. (2014). Simplified LC-MS/MS method enabling the determination of azithromycin in human plasma after a low 100mg dose administration. J Pharm Biomed Anal 100:184–9.
  • Kobuchi S, Aoki M, Inoue C, et al. (2016). Transport of azithromycin into extravascular space in rats. Antimicrob Agents Chemother 60:6823–7.
  • Kong XT, Fang HT, Jiang GQ, et al. (1993). Treatment of acute bronchiolitis with Chinese herbs. Arch Dis Child 68:468–71.
  • Law AH, Yang CL, Lau AS, Chan GC. (2017). Antiviral effect of forsythoside A from Forsythia suspensa (thunb.) Vahl fruit against influenza A virus through reduction of viral M1 protein. J Ethnopharmacol 209:236–47.
  • Li C, Dai Y, Duan YH, et al. (2014). A new lignan glycoside from Forsythia suspensa. Chin J Nat Med 12:697–9.
  • Li X, Sun S, Ling X, et al. (2017). Plasma and cerebrospinal fluid population pharmacokinetics of vancomycin in postoperative neurosurgical patients after combined intravenous and intraventricular administration. Eur J Clin Pharmacol 73:1599–607.
  • Li X, Sun S, Wang Q, Zhao Z. (2018a). Population pharmacokinetics of combined intravenous and local intrathecal administration of meropenem in aneurysm patients with suspected intracranial infections after craniotomy. Eur J Drug Metab Pharmacokinet 43:45–53.
  • Liu N, Chen X, Yin L. (2016). Clinical effect of azithromycin sequential therapy combined with shuanghuanglian oral solution on pediatric mycoplasma pneumonia and the impact on serum inflammatory cytokines levels and immunologic function. Pract J Cardiac Cereb Pneum Vasc Dis 24:94–7.
  • Li X, Wu Y, Sun S, et al. (2018b). Factors influencing norvancomycin concentration in plasma and cerebrospinal fluid in patients after craniotomy and dosing guideline: a population approach. Clin Ther 40:74–82 e71.
  • Ramaiah B, Nagaraja SH, Kapanigowda UG, et al. (2016). High azithromycin concentration in lungs by way of bovine serum albumin microspheres as targeted drug delivery: lung targeting efficiency in albino mice. Daru 24:14.
  • Salman S, Davis TM, Page-Sharp M, et al. (2015). Pharmacokinetics of transfer of azithromycin into the breast milk of African mothers. Antimicrob Agents Chemother 60:1592–9.
  • Sharma K, Mullangi R. (2013). A concise review of HPLC, LC-MS and LC-MS/MS methods for determination of azithromycin in various biological matrices. Biomed Chromatogr 27:1243–58.
  • Shen Y, Yin C, Su M, Tu J. (2010). Rapid, sensitive and selective liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the quantification of topically applied azithromycin in rabbit conjunctiva tissues. J Pharm Biomed Anal 52:99–104.
  • Soda M, Ito S, Matsumaru N, et al. (2018). Evaluation of the microbiological efficacy of a single 2-gram dose of extended-release azithromycin by population pharmacokinetics and simulation in Japanese patients with gonococcal urethritis. Antimicrob Agents Chemother 62:e01409–17.
  • Terkeltaub RA, Furst DE, Digiacinto JL, et al. (2011). Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum 63:2226–37.
  • Tian JC, Lin LF, Li XC, et al. (2015). Forsythiaside stability in pretreated rat plasma and its pharmacokinetics after i.v. administration. Anal Method 7:1809–15.
  • Tilelli JA, Smith KM, Pettignano R. (2006). Life-threatening bradyarrhythmia after massive azithromycin overdose. Pharmacotherapy 26:147–50.
  • Vodstrcil LA, Rupasinghe TWT, Kong FYS, et al. (2017). Measurement of tissue azithromycin levels in self-collected vaginal swabs post treatment using liquid chromatography and tandem mass spectrometry (LC-MS/MS). PLoS One 12:e0177615.
  • Wang H. (2018). Efficacy of shuanghuanglian oral liquid only for children combined with azithromycin in the treatment of mycoplasma pneumonia in children. Chin Foreign Med Res 16:25–7.
  • Wang H, Li X, Sun S, et al. (2018). Population pharmacokinetics and dosing simulations of ceftazidime in Chinese neonates. J Pharm Sci 107:1416–22.
  • Wang GQ, Xie YM, Wang LX, et al. (2017). Analysis of drug combination characteristics of Qingkailing injection for treating abnormal inflammatory factors in real world. Zhongguo Zhong Yao Za Zhi 42:1984–90.
  • Westphal JF. (2000). Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol 50:285–95.
  • Xing S, Peng Y, Wang M, et al. (2014). In vitro human fecal microbial metabolism of Forsythoside A and biological activities of its metabolites. Fitoterapia 99:159–65.
  • Zeng XY, Yuan W, Zhou L, et al. (2017). Forsythoside A exerts an anti-endotoxin effect by blocking the LPS/TLR4 signaling pathway and inhibiting Tregs in vitro. Int J Mol Med 40:243–50.
  • Zhang H, Chen Q, Zhou W, et al. (2013). Chinese medicine injection shuanghuanglian for treatment of acute upper respiratory tract infection: a systematic review of randomized controlled trials. Evid Based Complement Alternat Med 2013:987326.
  • Zhang J, Shang H, Zheng W, et al. (2010a). Systematic review on the compatibility of Shuanghuanglian injection combined with western medical injections. J Evid Based Med 3:27–36.
  • Zhang XY, Wang YR, Zhang Q, Lu W. (2010b). Population pharmacokinetics study of azithromycin oral formulations using NONMEM. Int J Clin Pharmacol Ther 48:662–9.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.